天然多糖做为纳米载体用于治疗炎症性肠病的研究进展  

Research Progress on Natural Polysaccharides as Nanocarriers for the Treatment of Inflammatory Bowel Disease

作　　者：刘欣欣 左翠玲 孙丽娜 李鑫[1] 王向涛 LIU Xinxin;ZUO Cuiling;SUN Lina;LI Xin;WANG Xiangtao(College of Pharmacy,Harbin University of Commerce,Harbin 150076,China;Institute of Medicinal Plant Development,Chinese Academy of Medical Sciences&Beijing Union Medical College,Beijing 100193,China)

机构地区：[1]哈尔滨商业大学药学院,黑龙江哈尔滨150076 [2]中国医学科学院,北京协和医学院,药用植物研究所,北京100193

出　　处：《现代食品科技》2023年第10期365-374,共10页Modern Food Science and Technology

基　　金：中央支持地方高校改革发展资金人才培养项目;中国医学科学院医学与健康创新工程(2021-I2M-1-071)。

摘　　要：炎症性肠病(IBD)是一种慢性、多因素、复发性疾病,以免疫系统紊乱和肠道炎症为特征。天然多糖具有pH响应性、胃耐受性、结肠微生物群的降解性和粘膜粘附性以及良好的抗炎活性和肠道菌群调节能力,被认为是设计IBD新型制剂的理想载体。将天然多糖做为纳米载体包裹药物靶向至结肠,既提高了药物的生物利用度又实现协同治疗的效果。文章综述了基于天然多糖纳米载体协同治疗IBD的机制以及做为载体的多糖在IBD治疗中的应用。Inflammatory bowel disease(IBD)is a chronic,multifactorial,recurrent disease characterized by immune system disorders and intestinal inflammation.Natural polysaccharides are pH-responsive,gastric tolerant,biodegradable and mucoadhesive by colonic microbiota,and have good anti-inflammatory and intestinal flora-regulating capacities,thereby being considered as ideal carriers for the design of novel preparations for IBD.Natural polysaccharides are used as nano-carriers to encapsulate drug targeting the colon,which not only improves the bioavailability of drugs,but also offers a synergistic therapy.This article reviews the mechanism underlying the synergistic treatment of IBD based on natural polysaccharide nanocarriers and the applications of polysaccharides as carriers in treating IBD.

关 键 词：炎症性肠病 天然多糖 载体 新型制剂 协同治疗 

分 类 号：R574[医药卫生—消化系统]